Opus Genetics (NASDAQ:IRD – Get Free Report) released its earnings results on Tuesday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.01, Zacks reports. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 59.72%. The firm had revenue of $3.87 million during the quarter, compared to analyst estimates of $1.17 million.
Opus Genetics Trading Down 5.7 %
Shares of IRD stock traded down $0.07 during trading hours on Wednesday, hitting $1.08. 174,208 shares of the company’s stock traded hands, compared to its average volume of 170,606. Opus Genetics has a 12-month low of $1.07 and a 12-month high of $3.40.
Analyst Upgrades and Downgrades
Separately, HC Wainwright assumed coverage on shares of Opus Genetics in a report on Wednesday. They set a “buy” rating and a $8.00 target price for the company.
About Opus Genetics
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Featured Stories
- Five stocks we like better than Opus Genetics
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Rocket Lab is the Right Stock for the Right Time
- Using the MarketBeat Dividend Tax Calculator
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Industrial Products Stocks Investing
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
